FRONT ONCOL 润色咨询

Frontiers in Oncology

出版年份:2011 年文章数:14479 投稿命中率: 开通期刊会员,数据随心看

出版周期:Irregular 自引率:2.1% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信<br>经验分享:还是比较好投的,2月多投的,4月多就接受了;祝大家好运!<br>11 Apr 2023 Article accepted for publication.<br>07 Apr 2023 Review of Review Editor 3 finalized.<br>01 Apr 2023 Review of Review Editor 4 finalized.<br>30 Mar 2023 Review of Review Editor 1 finalized.<br>17 Mar 2023 Interactive review forum activated.<br>07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183772, encodeId=9d0c2183e72db, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:感谢群里朋友的无私分享,对我第一篇SCI论文发表帮助很大,再次感谢!<br>献上我的投稿过程,供以后的朋友参考:<br>24 Jan 2024 Article accepted for publication. <br>08 Jan 2024 Review of Review Editor 1 finalized.<br>07 Jan 2024 Review of Review Editor 2 finalized.<br>03 Jan 2024 Corresponding Author Maoquan Zhang re-submitted manuscript.<br>29 Dec 2023 Interactive review forum activated.<br>11 Oct 2023 Corresponding Author Maoquan Zhang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqT3pba9RQEXLdriaBccULibKA31kTZvGCaJiaDmjyatyogUQM1Pt7OuGdpBTFtWq6owhwh1ScHVibbpg/132, createdBy=92a32211016, createdName=今日崛起, createdTime=Wed Jan 24 23:16:31 CST 2024, time=2024-01-24, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2195332, encodeId=2bf121953327a, content=偏重的研究方向:肿瘤<br>经验分享:各位大佬,请问这个拒稿意见是什么意思啊?<br>Reason:<br>Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f279231064, createdName=ms1000000764624599, createdTime=Mon Mar 25 22:43:40 CST 2024, time=2024-03-25, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2130197, encodeId=96a3213019e70, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;罕见基因变异;案例报道<br>经验分享:文章见刊了,好开心,之前参考了大家的投稿经验,分享一下我的投稿历程,传递好运!<br>2022.12.14号,提交Manuscript,Initial Validation <br>2022.12.19号,Editorial Assignment 稿件分配编辑<br>2023.01.23号,Independent Review Report, Reviewer 1返回审稿意见,这个审稿人提的意见很专业,态度中立<br>2023.03.14号,两个月没动静,给编辑发了一封催稿邮件,得到回应<br>2023.03.15号,Reviewer 2返回审稿意见,直接同意发表,审稿意见还是需要在编辑界面单独回复的,限期14天内<br>2023.03.16,Interactive review交互评审<br>2023.03.24,提交第一轮审稿意见和修改稿<br>2023.03.28,Review Finalized<br>2023.04.07,accepted <br>2023.04.12,Author's Proof,要求两天内提交<br>2023.04.25,支付版面费,2020 USD,限期一个月<br>2023.04.28,在线发表。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Fri May 05 09:41:42 CST 2023, time=2023-05-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向:肿瘤;免疫治疗;生信<br>经验分享:这个需要多久到分配编辑呀,在initial validation 4.5天了…… 生信又做了6个验证试验,不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0<br>偏重的研究方向:诊断;肿瘤;临床<br>经验分享:临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向:肿瘤<br>经验分享:来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右,这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=290, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151127, encodeId=429b215112e2a, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:症状管理;急性白血病<br>经验分享:来还愿了。分享一下历程。Received date: 09 Jun 2023<br>Editorial assignment start date: 13 Jun 2023<br>Independent review start date: 19 Jun 2023<br>Interactive review activated date: 05 Jul 2023<br>Review finalized date: 24 Jul 2023<br>Final validation date: 02 Aug 2023<br>Manucript accepted: 02 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477a5626989, createdName=ms3000001338105201, createdTime=Thu Aug 03 16:40:57 CST 2023, time=2023-08-03, status=1, ipAttribution=广东省)]
    2023-04-28 ms1000001631708013 来自浙江省

    审稿速度:2.0 | 投稿命中率:75.0
    偏重的研究方向:肿瘤;生信
    经验分享:还是比较好投的,2月多投的,4月多就接受了;祝大家好运!
    11 Apr 2023 Article accepted for publication.
    07 Apr 2023 Review of Review Editor 3 finalized.
    01 Apr 2023 Review of Review Editor 4 finalized.
    30 Mar 2023 Review of Review Editor 1 finalized.
    17 Mar 2023 Interactive review forum activated.
    07 Feb 2023 submitted manuscript

    6

    展开6条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信<br>经验分享:还是比较好投的,2月多投的,4月多就接受了;祝大家好运!<br>11 Apr 2023 Article accepted for publication.<br>07 Apr 2023 Review of Review Editor 3 finalized.<br>01 Apr 2023 Review of Review Editor 4 finalized.<br>30 Mar 2023 Review of Review Editor 1 finalized.<br>17 Mar 2023 Interactive review forum activated.<br>07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183772, encodeId=9d0c2183e72db, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:感谢群里朋友的无私分享,对我第一篇SCI论文发表帮助很大,再次感谢!<br>献上我的投稿过程,供以后的朋友参考:<br>24 Jan 2024 Article accepted for publication. <br>08 Jan 2024 Review of Review Editor 1 finalized.<br>07 Jan 2024 Review of Review Editor 2 finalized.<br>03 Jan 2024 Corresponding Author Maoquan Zhang re-submitted manuscript.<br>29 Dec 2023 Interactive review forum activated.<br>11 Oct 2023 Corresponding Author Maoquan Zhang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqT3pba9RQEXLdriaBccULibKA31kTZvGCaJiaDmjyatyogUQM1Pt7OuGdpBTFtWq6owhwh1ScHVibbpg/132, createdBy=92a32211016, createdName=今日崛起, createdTime=Wed Jan 24 23:16:31 CST 2024, time=2024-01-24, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2195332, encodeId=2bf121953327a, content=偏重的研究方向:肿瘤<br>经验分享:各位大佬,请问这个拒稿意见是什么意思啊?<br>Reason:<br>Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f279231064, createdName=ms1000000764624599, createdTime=Mon Mar 25 22:43:40 CST 2024, time=2024-03-25, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2130197, encodeId=96a3213019e70, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;罕见基因变异;案例报道<br>经验分享:文章见刊了,好开心,之前参考了大家的投稿经验,分享一下我的投稿历程,传递好运!<br>2022.12.14号,提交Manuscript,Initial Validation <br>2022.12.19号,Editorial Assignment 稿件分配编辑<br>2023.01.23号,Independent Review Report, Reviewer 1返回审稿意见,这个审稿人提的意见很专业,态度中立<br>2023.03.14号,两个月没动静,给编辑发了一封催稿邮件,得到回应<br>2023.03.15号,Reviewer 2返回审稿意见,直接同意发表,审稿意见还是需要在编辑界面单独回复的,限期14天内<br>2023.03.16,Interactive review交互评审<br>2023.03.24,提交第一轮审稿意见和修改稿<br>2023.03.28,Review Finalized<br>2023.04.07,accepted <br>2023.04.12,Author's Proof,要求两天内提交<br>2023.04.25,支付版面费,2020 USD,限期一个月<br>2023.04.28,在线发表。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Fri May 05 09:41:42 CST 2023, time=2023-05-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向:肿瘤;免疫治疗;生信<br>经验分享:这个需要多久到分配编辑呀,在initial validation 4.5天了…… 生信又做了6个验证试验,不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0<br>偏重的研究方向:诊断;肿瘤;临床<br>经验分享:临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向:肿瘤<br>经验分享:来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右,这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=290, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151127, encodeId=429b215112e2a, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:症状管理;急性白血病<br>经验分享:来还愿了。分享一下历程。Received date: 09 Jun 2023<br>Editorial assignment start date: 13 Jun 2023<br>Independent review start date: 19 Jun 2023<br>Interactive review activated date: 05 Jul 2023<br>Review finalized date: 24 Jul 2023<br>Final validation date: 02 Aug 2023<br>Manucript accepted: 02 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477a5626989, createdName=ms3000001338105201, createdTime=Thu Aug 03 16:40:57 CST 2023, time=2023-08-03, status=1, ipAttribution=广东省)]
    2024-01-24 今日崛起 来自福建省

    审稿速度:3.0 | 投稿命中率:50.0
    偏重的研究方向:肿瘤
    经验分享:感谢群里朋友的无私分享,对我第一篇SCI论文发表帮助很大,再次感谢!
    献上我的投稿过程,供以后的朋友参考:
    24 Jan 2024 Article accepted for publication.
    08 Jan 2024 Review of Review Editor 1 finalized.
    07 Jan 2024 Review of Review Editor 2 finalized.
    03 Jan 2024 Corresponding Author Maoquan Zhang re-submitted manuscript.
    29 Dec 2023 Interactive review forum activated.
    11 Oct 2023 Corresponding Author Maoquan Zhang submitted manuscript.

    2

    展开2条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信<br>经验分享:还是比较好投的,2月多投的,4月多就接受了;祝大家好运!<br>11 Apr 2023 Article accepted for publication.<br>07 Apr 2023 Review of Review Editor 3 finalized.<br>01 Apr 2023 Review of Review Editor 4 finalized.<br>30 Mar 2023 Review of Review Editor 1 finalized.<br>17 Mar 2023 Interactive review forum activated.<br>07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183772, encodeId=9d0c2183e72db, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:感谢群里朋友的无私分享,对我第一篇SCI论文发表帮助很大,再次感谢!<br>献上我的投稿过程,供以后的朋友参考:<br>24 Jan 2024 Article accepted for publication. <br>08 Jan 2024 Review of Review Editor 1 finalized.<br>07 Jan 2024 Review of Review Editor 2 finalized.<br>03 Jan 2024 Corresponding Author Maoquan Zhang re-submitted manuscript.<br>29 Dec 2023 Interactive review forum activated.<br>11 Oct 2023 Corresponding Author Maoquan Zhang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqT3pba9RQEXLdriaBccULibKA31kTZvGCaJiaDmjyatyogUQM1Pt7OuGdpBTFtWq6owhwh1ScHVibbpg/132, createdBy=92a32211016, createdName=今日崛起, createdTime=Wed Jan 24 23:16:31 CST 2024, time=2024-01-24, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2195332, encodeId=2bf121953327a, content=偏重的研究方向:肿瘤<br>经验分享:各位大佬,请问这个拒稿意见是什么意思啊?<br>Reason:<br>Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f279231064, createdName=ms1000000764624599, createdTime=Mon Mar 25 22:43:40 CST 2024, time=2024-03-25, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2130197, encodeId=96a3213019e70, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;罕见基因变异;案例报道<br>经验分享:文章见刊了,好开心,之前参考了大家的投稿经验,分享一下我的投稿历程,传递好运!<br>2022.12.14号,提交Manuscript,Initial Validation <br>2022.12.19号,Editorial Assignment 稿件分配编辑<br>2023.01.23号,Independent Review Report, Reviewer 1返回审稿意见,这个审稿人提的意见很专业,态度中立<br>2023.03.14号,两个月没动静,给编辑发了一封催稿邮件,得到回应<br>2023.03.15号,Reviewer 2返回审稿意见,直接同意发表,审稿意见还是需要在编辑界面单独回复的,限期14天内<br>2023.03.16,Interactive review交互评审<br>2023.03.24,提交第一轮审稿意见和修改稿<br>2023.03.28,Review Finalized<br>2023.04.07,accepted <br>2023.04.12,Author's Proof,要求两天内提交<br>2023.04.25,支付版面费,2020 USD,限期一个月<br>2023.04.28,在线发表。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Fri May 05 09:41:42 CST 2023, time=2023-05-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向:肿瘤;免疫治疗;生信<br>经验分享:这个需要多久到分配编辑呀,在initial validation 4.5天了…… 生信又做了6个验证试验,不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0<br>偏重的研究方向:诊断;肿瘤;临床<br>经验分享:临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向:肿瘤<br>经验分享:来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右,这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=290, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151127, encodeId=429b215112e2a, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:症状管理;急性白血病<br>经验分享:来还愿了。分享一下历程。Received date: 09 Jun 2023<br>Editorial assignment start date: 13 Jun 2023<br>Independent review start date: 19 Jun 2023<br>Interactive review activated date: 05 Jul 2023<br>Review finalized date: 24 Jul 2023<br>Final validation date: 02 Aug 2023<br>Manucript accepted: 02 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477a5626989, createdName=ms3000001338105201, createdTime=Thu Aug 03 16:40:57 CST 2023, time=2023-08-03, status=1, ipAttribution=广东省)]
    2024-03-25 ms1000000764624599 来自贵州省

    偏重的研究方向:肿瘤
    经验分享:各位大佬,请问这个拒稿意见是什么意思啊?
    Reason:
    Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication.

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信<br>经验分享:还是比较好投的,2月多投的,4月多就接受了;祝大家好运!<br>11 Apr 2023 Article accepted for publication.<br>07 Apr 2023 Review of Review Editor 3 finalized.<br>01 Apr 2023 Review of Review Editor 4 finalized.<br>30 Mar 2023 Review of Review Editor 1 finalized.<br>17 Mar 2023 Interactive review forum activated.<br>07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183772, encodeId=9d0c2183e72db, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:感谢群里朋友的无私分享,对我第一篇SCI论文发表帮助很大,再次感谢!<br>献上我的投稿过程,供以后的朋友参考:<br>24 Jan 2024 Article accepted for publication. <br>08 Jan 2024 Review of Review Editor 1 finalized.<br>07 Jan 2024 Review of Review Editor 2 finalized.<br>03 Jan 2024 Corresponding Author Maoquan Zhang re-submitted manuscript.<br>29 Dec 2023 Interactive review forum activated.<br>11 Oct 2023 Corresponding Author Maoquan Zhang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqT3pba9RQEXLdriaBccULibKA31kTZvGCaJiaDmjyatyogUQM1Pt7OuGdpBTFtWq6owhwh1ScHVibbpg/132, createdBy=92a32211016, createdName=今日崛起, createdTime=Wed Jan 24 23:16:31 CST 2024, time=2024-01-24, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2195332, encodeId=2bf121953327a, content=偏重的研究方向:肿瘤<br>经验分享:各位大佬,请问这个拒稿意见是什么意思啊?<br>Reason:<br>Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f279231064, createdName=ms1000000764624599, createdTime=Mon Mar 25 22:43:40 CST 2024, time=2024-03-25, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2130197, encodeId=96a3213019e70, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;罕见基因变异;案例报道<br>经验分享:文章见刊了,好开心,之前参考了大家的投稿经验,分享一下我的投稿历程,传递好运!<br>2022.12.14号,提交Manuscript,Initial Validation <br>2022.12.19号,Editorial Assignment 稿件分配编辑<br>2023.01.23号,Independent Review Report, Reviewer 1返回审稿意见,这个审稿人提的意见很专业,态度中立<br>2023.03.14号,两个月没动静,给编辑发了一封催稿邮件,得到回应<br>2023.03.15号,Reviewer 2返回审稿意见,直接同意发表,审稿意见还是需要在编辑界面单独回复的,限期14天内<br>2023.03.16,Interactive review交互评审<br>2023.03.24,提交第一轮审稿意见和修改稿<br>2023.03.28,Review Finalized<br>2023.04.07,accepted <br>2023.04.12,Author's Proof,要求两天内提交<br>2023.04.25,支付版面费,2020 USD,限期一个月<br>2023.04.28,在线发表。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Fri May 05 09:41:42 CST 2023, time=2023-05-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向:肿瘤;免疫治疗;生信<br>经验分享:这个需要多久到分配编辑呀,在initial validation 4.5天了…… 生信又做了6个验证试验,不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0<br>偏重的研究方向:诊断;肿瘤;临床<br>经验分享:临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向:肿瘤<br>经验分享:来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右,这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=290, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151127, encodeId=429b215112e2a, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:症状管理;急性白血病<br>经验分享:来还愿了。分享一下历程。Received date: 09 Jun 2023<br>Editorial assignment start date: 13 Jun 2023<br>Independent review start date: 19 Jun 2023<br>Interactive review activated date: 05 Jul 2023<br>Review finalized date: 24 Jul 2023<br>Final validation date: 02 Aug 2023<br>Manucript accepted: 02 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477a5626989, createdName=ms3000001338105201, createdTime=Thu Aug 03 16:40:57 CST 2023, time=2023-08-03, status=1, ipAttribution=广东省)]
    2023-05-05 ms2000000984739514 来自浙江省

    审稿速度:2.0 | 投稿命中率:75.0
    偏重的研究方向:肿瘤;罕见基因变异;案例报道
    经验分享:文章见刊了,好开心,之前参考了大家的投稿经验,分享一下我的投稿历程,传递好运!
    2022.12.14号,提交Manuscript,Initial Validation
    2022.12.19号,Editorial Assignment 稿件分配编辑
    2023.01.23号,Independent Review Report, Reviewer 1返回审稿意见,这个审稿人提的意见很专业,态度中立
    2023.03.14号,两个月没动静,给编辑发了一封催稿邮件,得到回应
    2023.03.15号,Reviewer 2返回审稿意见,直接同意发表,审稿意见还是需要在编辑界面单独回复的,限期14天内
    2023.03.16,Interactive review交互评审
    2023.03.24,提交第一轮审稿意见和修改稿
    2023.03.28,Review Finalized
    2023.04.07,accepted
    2023.04.12,Author's Proof,要求两天内提交
    2023.04.25,支付版面费,2020 USD,限期一个月
    2023.04.28,在线发表。

    4

    展开4条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信<br>经验分享:还是比较好投的,2月多投的,4月多就接受了;祝大家好运!<br>11 Apr 2023 Article accepted for publication.<br>07 Apr 2023 Review of Review Editor 3 finalized.<br>01 Apr 2023 Review of Review Editor 4 finalized.<br>30 Mar 2023 Review of Review Editor 1 finalized.<br>17 Mar 2023 Interactive review forum activated.<br>07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183772, encodeId=9d0c2183e72db, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:感谢群里朋友的无私分享,对我第一篇SCI论文发表帮助很大,再次感谢!<br>献上我的投稿过程,供以后的朋友参考:<br>24 Jan 2024 Article accepted for publication. <br>08 Jan 2024 Review of Review Editor 1 finalized.<br>07 Jan 2024 Review of Review Editor 2 finalized.<br>03 Jan 2024 Corresponding Author Maoquan Zhang re-submitted manuscript.<br>29 Dec 2023 Interactive review forum activated.<br>11 Oct 2023 Corresponding Author Maoquan Zhang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqT3pba9RQEXLdriaBccULibKA31kTZvGCaJiaDmjyatyogUQM1Pt7OuGdpBTFtWq6owhwh1ScHVibbpg/132, createdBy=92a32211016, createdName=今日崛起, createdTime=Wed Jan 24 23:16:31 CST 2024, time=2024-01-24, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2195332, encodeId=2bf121953327a, content=偏重的研究方向:肿瘤<br>经验分享:各位大佬,请问这个拒稿意见是什么意思啊?<br>Reason:<br>Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f279231064, createdName=ms1000000764624599, createdTime=Mon Mar 25 22:43:40 CST 2024, time=2024-03-25, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2130197, encodeId=96a3213019e70, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;罕见基因变异;案例报道<br>经验分享:文章见刊了,好开心,之前参考了大家的投稿经验,分享一下我的投稿历程,传递好运!<br>2022.12.14号,提交Manuscript,Initial Validation <br>2022.12.19号,Editorial Assignment 稿件分配编辑<br>2023.01.23号,Independent Review Report, Reviewer 1返回审稿意见,这个审稿人提的意见很专业,态度中立<br>2023.03.14号,两个月没动静,给编辑发了一封催稿邮件,得到回应<br>2023.03.15号,Reviewer 2返回审稿意见,直接同意发表,审稿意见还是需要在编辑界面单独回复的,限期14天内<br>2023.03.16,Interactive review交互评审<br>2023.03.24,提交第一轮审稿意见和修改稿<br>2023.03.28,Review Finalized<br>2023.04.07,accepted <br>2023.04.12,Author's Proof,要求两天内提交<br>2023.04.25,支付版面费,2020 USD,限期一个月<br>2023.04.28,在线发表。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Fri May 05 09:41:42 CST 2023, time=2023-05-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向:肿瘤;免疫治疗;生信<br>经验分享:这个需要多久到分配编辑呀,在initial validation 4.5天了…… 生信又做了6个验证试验,不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0<br>偏重的研究方向:诊断;肿瘤;临床<br>经验分享:临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向:肿瘤<br>经验分享:来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右,这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=290, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151127, encodeId=429b215112e2a, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:症状管理;急性白血病<br>经验分享:来还愿了。分享一下历程。Received date: 09 Jun 2023<br>Editorial assignment start date: 13 Jun 2023<br>Independent review start date: 19 Jun 2023<br>Interactive review activated date: 05 Jul 2023<br>Review finalized date: 24 Jul 2023<br>Final validation date: 02 Aug 2023<br>Manucript accepted: 02 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477a5626989, createdName=ms3000001338105201, createdTime=Thu Aug 03 16:40:57 CST 2023, time=2023-08-03, status=1, ipAttribution=广东省)]
    2024-03-21 ms4000000517261689 来自山东省

    偏重的研究方向:肿瘤;免疫治疗;生信
    经验分享:这个需要多久到分配编辑呀,在initial validation 4.5天了…… 生信又做了6个验证试验,不知道稳不稳…

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信<br>经验分享:还是比较好投的,2月多投的,4月多就接受了;祝大家好运!<br>11 Apr 2023 Article accepted for publication.<br>07 Apr 2023 Review of Review Editor 3 finalized.<br>01 Apr 2023 Review of Review Editor 4 finalized.<br>30 Mar 2023 Review of Review Editor 1 finalized.<br>17 Mar 2023 Interactive review forum activated.<br>07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183772, encodeId=9d0c2183e72db, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:感谢群里朋友的无私分享,对我第一篇SCI论文发表帮助很大,再次感谢!<br>献上我的投稿过程,供以后的朋友参考:<br>24 Jan 2024 Article accepted for publication. <br>08 Jan 2024 Review of Review Editor 1 finalized.<br>07 Jan 2024 Review of Review Editor 2 finalized.<br>03 Jan 2024 Corresponding Author Maoquan Zhang re-submitted manuscript.<br>29 Dec 2023 Interactive review forum activated.<br>11 Oct 2023 Corresponding Author Maoquan Zhang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqT3pba9RQEXLdriaBccULibKA31kTZvGCaJiaDmjyatyogUQM1Pt7OuGdpBTFtWq6owhwh1ScHVibbpg/132, createdBy=92a32211016, createdName=今日崛起, createdTime=Wed Jan 24 23:16:31 CST 2024, time=2024-01-24, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2195332, encodeId=2bf121953327a, content=偏重的研究方向:肿瘤<br>经验分享:各位大佬,请问这个拒稿意见是什么意思啊?<br>Reason:<br>Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f279231064, createdName=ms1000000764624599, createdTime=Mon Mar 25 22:43:40 CST 2024, time=2024-03-25, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2130197, encodeId=96a3213019e70, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;罕见基因变异;案例报道<br>经验分享:文章见刊了,好开心,之前参考了大家的投稿经验,分享一下我的投稿历程,传递好运!<br>2022.12.14号,提交Manuscript,Initial Validation <br>2022.12.19号,Editorial Assignment 稿件分配编辑<br>2023.01.23号,Independent Review Report, Reviewer 1返回审稿意见,这个审稿人提的意见很专业,态度中立<br>2023.03.14号,两个月没动静,给编辑发了一封催稿邮件,得到回应<br>2023.03.15号,Reviewer 2返回审稿意见,直接同意发表,审稿意见还是需要在编辑界面单独回复的,限期14天内<br>2023.03.16,Interactive review交互评审<br>2023.03.24,提交第一轮审稿意见和修改稿<br>2023.03.28,Review Finalized<br>2023.04.07,accepted <br>2023.04.12,Author's Proof,要求两天内提交<br>2023.04.25,支付版面费,2020 USD,限期一个月<br>2023.04.28,在线发表。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Fri May 05 09:41:42 CST 2023, time=2023-05-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向:肿瘤;免疫治疗;生信<br>经验分享:这个需要多久到分配编辑呀,在initial validation 4.5天了…… 生信又做了6个验证试验,不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0<br>偏重的研究方向:诊断;肿瘤;临床<br>经验分享:临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向:肿瘤<br>经验分享:来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右,这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=290, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151127, encodeId=429b215112e2a, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:症状管理;急性白血病<br>经验分享:来还愿了。分享一下历程。Received date: 09 Jun 2023<br>Editorial assignment start date: 13 Jun 2023<br>Independent review start date: 19 Jun 2023<br>Interactive review activated date: 05 Jul 2023<br>Review finalized date: 24 Jul 2023<br>Final validation date: 02 Aug 2023<br>Manucript accepted: 02 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477a5626989, createdName=ms3000001338105201, createdTime=Thu Aug 03 16:40:57 CST 2023, time=2023-08-03, status=1, ipAttribution=广东省)]
    2024-01-31 mastermaus 来自湖北省

    审稿速度:1.0
    偏重的研究方向:诊断;肿瘤;临床
    经验分享:临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新

    3

    展开3条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信<br>经验分享:还是比较好投的,2月多投的,4月多就接受了;祝大家好运!<br>11 Apr 2023 Article accepted for publication.<br>07 Apr 2023 Review of Review Editor 3 finalized.<br>01 Apr 2023 Review of Review Editor 4 finalized.<br>30 Mar 2023 Review of Review Editor 1 finalized.<br>17 Mar 2023 Interactive review forum activated.<br>07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183772, encodeId=9d0c2183e72db, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:感谢群里朋友的无私分享,对我第一篇SCI论文发表帮助很大,再次感谢!<br>献上我的投稿过程,供以后的朋友参考:<br>24 Jan 2024 Article accepted for publication. <br>08 Jan 2024 Review of Review Editor 1 finalized.<br>07 Jan 2024 Review of Review Editor 2 finalized.<br>03 Jan 2024 Corresponding Author Maoquan Zhang re-submitted manuscript.<br>29 Dec 2023 Interactive review forum activated.<br>11 Oct 2023 Corresponding Author Maoquan Zhang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqT3pba9RQEXLdriaBccULibKA31kTZvGCaJiaDmjyatyogUQM1Pt7OuGdpBTFtWq6owhwh1ScHVibbpg/132, createdBy=92a32211016, createdName=今日崛起, createdTime=Wed Jan 24 23:16:31 CST 2024, time=2024-01-24, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2195332, encodeId=2bf121953327a, content=偏重的研究方向:肿瘤<br>经验分享:各位大佬,请问这个拒稿意见是什么意思啊?<br>Reason:<br>Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f279231064, createdName=ms1000000764624599, createdTime=Mon Mar 25 22:43:40 CST 2024, time=2024-03-25, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2130197, encodeId=96a3213019e70, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;罕见基因变异;案例报道<br>经验分享:文章见刊了,好开心,之前参考了大家的投稿经验,分享一下我的投稿历程,传递好运!<br>2022.12.14号,提交Manuscript,Initial Validation <br>2022.12.19号,Editorial Assignment 稿件分配编辑<br>2023.01.23号,Independent Review Report, Reviewer 1返回审稿意见,这个审稿人提的意见很专业,态度中立<br>2023.03.14号,两个月没动静,给编辑发了一封催稿邮件,得到回应<br>2023.03.15号,Reviewer 2返回审稿意见,直接同意发表,审稿意见还是需要在编辑界面单独回复的,限期14天内<br>2023.03.16,Interactive review交互评审<br>2023.03.24,提交第一轮审稿意见和修改稿<br>2023.03.28,Review Finalized<br>2023.04.07,accepted <br>2023.04.12,Author's Proof,要求两天内提交<br>2023.04.25,支付版面费,2020 USD,限期一个月<br>2023.04.28,在线发表。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Fri May 05 09:41:42 CST 2023, time=2023-05-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向:肿瘤;免疫治疗;生信<br>经验分享:这个需要多久到分配编辑呀,在initial validation 4.5天了…… 生信又做了6个验证试验,不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0<br>偏重的研究方向:诊断;肿瘤;临床<br>经验分享:临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向:肿瘤<br>经验分享:来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右,这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=290, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151127, encodeId=429b215112e2a, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:症状管理;急性白血病<br>经验分享:来还愿了。分享一下历程。Received date: 09 Jun 2023<br>Editorial assignment start date: 13 Jun 2023<br>Independent review start date: 19 Jun 2023<br>Interactive review activated date: 05 Jul 2023<br>Review finalized date: 24 Jul 2023<br>Final validation date: 02 Aug 2023<br>Manucript accepted: 02 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477a5626989, createdName=ms3000001338105201, createdTime=Thu Aug 03 16:40:57 CST 2023, time=2023-08-03, status=1, ipAttribution=广东省)]
    2024-03-11 第一篇一定要中啊 来自江苏省

    审稿速度:24.0 | 投稿命中率:5.0
    偏重的研究方向:肿瘤
    经验分享:其实是很难的

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信<br>经验分享:还是比较好投的,2月多投的,4月多就接受了;祝大家好运!<br>11 Apr 2023 Article accepted for publication.<br>07 Apr 2023 Review of Review Editor 3 finalized.<br>01 Apr 2023 Review of Review Editor 4 finalized.<br>30 Mar 2023 Review of Review Editor 1 finalized.<br>17 Mar 2023 Interactive review forum activated.<br>07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183772, encodeId=9d0c2183e72db, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:感谢群里朋友的无私分享,对我第一篇SCI论文发表帮助很大,再次感谢!<br>献上我的投稿过程,供以后的朋友参考:<br>24 Jan 2024 Article accepted for publication. <br>08 Jan 2024 Review of Review Editor 1 finalized.<br>07 Jan 2024 Review of Review Editor 2 finalized.<br>03 Jan 2024 Corresponding Author Maoquan Zhang re-submitted manuscript.<br>29 Dec 2023 Interactive review forum activated.<br>11 Oct 2023 Corresponding Author Maoquan Zhang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqT3pba9RQEXLdriaBccULibKA31kTZvGCaJiaDmjyatyogUQM1Pt7OuGdpBTFtWq6owhwh1ScHVibbpg/132, createdBy=92a32211016, createdName=今日崛起, createdTime=Wed Jan 24 23:16:31 CST 2024, time=2024-01-24, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2195332, encodeId=2bf121953327a, content=偏重的研究方向:肿瘤<br>经验分享:各位大佬,请问这个拒稿意见是什么意思啊?<br>Reason:<br>Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f279231064, createdName=ms1000000764624599, createdTime=Mon Mar 25 22:43:40 CST 2024, time=2024-03-25, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2130197, encodeId=96a3213019e70, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;罕见基因变异;案例报道<br>经验分享:文章见刊了,好开心,之前参考了大家的投稿经验,分享一下我的投稿历程,传递好运!<br>2022.12.14号,提交Manuscript,Initial Validation <br>2022.12.19号,Editorial Assignment 稿件分配编辑<br>2023.01.23号,Independent Review Report, Reviewer 1返回审稿意见,这个审稿人提的意见很专业,态度中立<br>2023.03.14号,两个月没动静,给编辑发了一封催稿邮件,得到回应<br>2023.03.15号,Reviewer 2返回审稿意见,直接同意发表,审稿意见还是需要在编辑界面单独回复的,限期14天内<br>2023.03.16,Interactive review交互评审<br>2023.03.24,提交第一轮审稿意见和修改稿<br>2023.03.28,Review Finalized<br>2023.04.07,accepted <br>2023.04.12,Author's Proof,要求两天内提交<br>2023.04.25,支付版面费,2020 USD,限期一个月<br>2023.04.28,在线发表。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Fri May 05 09:41:42 CST 2023, time=2023-05-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向:肿瘤;免疫治疗;生信<br>经验分享:这个需要多久到分配编辑呀,在initial validation 4.5天了…… 生信又做了6个验证试验,不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0<br>偏重的研究方向:诊断;肿瘤;临床<br>经验分享:临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向:肿瘤<br>经验分享:来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右,这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=290, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151127, encodeId=429b215112e2a, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:症状管理;急性白血病<br>经验分享:来还愿了。分享一下历程。Received date: 09 Jun 2023<br>Editorial assignment start date: 13 Jun 2023<br>Independent review start date: 19 Jun 2023<br>Interactive review activated date: 05 Jul 2023<br>Review finalized date: 24 Jul 2023<br>Final validation date: 02 Aug 2023<br>Manucript accepted: 02 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477a5626989, createdName=ms3000001338105201, createdTime=Thu Aug 03 16:40:57 CST 2023, time=2023-08-03, status=1, ipAttribution=广东省)]
    2023-10-30 小鹏友 来自重庆

    审稿速度:3.0 | 投稿命中率:95.0
    偏重的研究方向:肿瘤
    经验分享:非常水……😌😌😌😌

    6

    展开6条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信<br>经验分享:还是比较好投的,2月多投的,4月多就接受了;祝大家好运!<br>11 Apr 2023 Article accepted for publication.<br>07 Apr 2023 Review of Review Editor 3 finalized.<br>01 Apr 2023 Review of Review Editor 4 finalized.<br>30 Mar 2023 Review of Review Editor 1 finalized.<br>17 Mar 2023 Interactive review forum activated.<br>07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183772, encodeId=9d0c2183e72db, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:感谢群里朋友的无私分享,对我第一篇SCI论文发表帮助很大,再次感谢!<br>献上我的投稿过程,供以后的朋友参考:<br>24 Jan 2024 Article accepted for publication. <br>08 Jan 2024 Review of Review Editor 1 finalized.<br>07 Jan 2024 Review of Review Editor 2 finalized.<br>03 Jan 2024 Corresponding Author Maoquan Zhang re-submitted manuscript.<br>29 Dec 2023 Interactive review forum activated.<br>11 Oct 2023 Corresponding Author Maoquan Zhang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqT3pba9RQEXLdriaBccULibKA31kTZvGCaJiaDmjyatyogUQM1Pt7OuGdpBTFtWq6owhwh1ScHVibbpg/132, createdBy=92a32211016, createdName=今日崛起, createdTime=Wed Jan 24 23:16:31 CST 2024, time=2024-01-24, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2195332, encodeId=2bf121953327a, content=偏重的研究方向:肿瘤<br>经验分享:各位大佬,请问这个拒稿意见是什么意思啊?<br>Reason:<br>Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f279231064, createdName=ms1000000764624599, createdTime=Mon Mar 25 22:43:40 CST 2024, time=2024-03-25, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2130197, encodeId=96a3213019e70, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;罕见基因变异;案例报道<br>经验分享:文章见刊了,好开心,之前参考了大家的投稿经验,分享一下我的投稿历程,传递好运!<br>2022.12.14号,提交Manuscript,Initial Validation <br>2022.12.19号,Editorial Assignment 稿件分配编辑<br>2023.01.23号,Independent Review Report, Reviewer 1返回审稿意见,这个审稿人提的意见很专业,态度中立<br>2023.03.14号,两个月没动静,给编辑发了一封催稿邮件,得到回应<br>2023.03.15号,Reviewer 2返回审稿意见,直接同意发表,审稿意见还是需要在编辑界面单独回复的,限期14天内<br>2023.03.16,Interactive review交互评审<br>2023.03.24,提交第一轮审稿意见和修改稿<br>2023.03.28,Review Finalized<br>2023.04.07,accepted <br>2023.04.12,Author's Proof,要求两天内提交<br>2023.04.25,支付版面费,2020 USD,限期一个月<br>2023.04.28,在线发表。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Fri May 05 09:41:42 CST 2023, time=2023-05-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向:肿瘤;免疫治疗;生信<br>经验分享:这个需要多久到分配编辑呀,在initial validation 4.5天了…… 生信又做了6个验证试验,不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0<br>偏重的研究方向:诊断;肿瘤;临床<br>经验分享:临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向:肿瘤<br>经验分享:来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右,这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=290, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151127, encodeId=429b215112e2a, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:症状管理;急性白血病<br>经验分享:来还愿了。分享一下历程。Received date: 09 Jun 2023<br>Editorial assignment start date: 13 Jun 2023<br>Independent review start date: 19 Jun 2023<br>Interactive review activated date: 05 Jul 2023<br>Review finalized date: 24 Jul 2023<br>Final validation date: 02 Aug 2023<br>Manucript accepted: 02 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477a5626989, createdName=ms3000001338105201, createdTime=Thu Aug 03 16:40:57 CST 2023, time=2023-08-03, status=1, ipAttribution=广东省)]
    2021-09-17 146e0980m70暂无昵称

    审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0
    偏重的研究方向:肿瘤
    经验分享:来还愿了
    修回3天后审稿人全部endorse
    第4天就直接accept了
    从投稿到接收差不多两个月左右,这个速度简直感激

    71

    展开71条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信<br>经验分享:还是比较好投的,2月多投的,4月多就接受了;祝大家好运!<br>11 Apr 2023 Article accepted for publication.<br>07 Apr 2023 Review of Review Editor 3 finalized.<br>01 Apr 2023 Review of Review Editor 4 finalized.<br>30 Mar 2023 Review of Review Editor 1 finalized.<br>17 Mar 2023 Interactive review forum activated.<br>07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2183772, encodeId=9d0c2183e72db, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤<br>经验分享:感谢群里朋友的无私分享,对我第一篇SCI论文发表帮助很大,再次感谢!<br>献上我的投稿过程,供以后的朋友参考:<br>24 Jan 2024 Article accepted for publication. <br>08 Jan 2024 Review of Review Editor 1 finalized.<br>07 Jan 2024 Review of Review Editor 2 finalized.<br>03 Jan 2024 Corresponding Author Maoquan Zhang re-submitted manuscript.<br>29 Dec 2023 Interactive review forum activated.<br>11 Oct 2023 Corresponding Author Maoquan Zhang submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqT3pba9RQEXLdriaBccULibKA31kTZvGCaJiaDmjyatyogUQM1Pt7OuGdpBTFtWq6owhwh1ScHVibbpg/132, createdBy=92a32211016, createdName=今日崛起, createdTime=Wed Jan 24 23:16:31 CST 2024, time=2024-01-24, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2195332, encodeId=2bf121953327a, content=偏重的研究方向:肿瘤<br>经验分享:各位大佬,请问这个拒稿意见是什么意思啊?<br>Reason:<br>Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f279231064, createdName=ms1000000764624599, createdTime=Mon Mar 25 22:43:40 CST 2024, time=2024-03-25, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2130197, encodeId=96a3213019e70, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;罕见基因变异;案例报道<br>经验分享:文章见刊了,好开心,之前参考了大家的投稿经验,分享一下我的投稿历程,传递好运!<br>2022.12.14号,提交Manuscript,Initial Validation <br>2022.12.19号,Editorial Assignment 稿件分配编辑<br>2023.01.23号,Independent Review Report, Reviewer 1返回审稿意见,这个审稿人提的意见很专业,态度中立<br>2023.03.14号,两个月没动静,给编辑发了一封催稿邮件,得到回应<br>2023.03.15号,Reviewer 2返回审稿意见,直接同意发表,审稿意见还是需要在编辑界面单独回复的,限期14天内<br>2023.03.16,Interactive review交互评审<br>2023.03.24,提交第一轮审稿意见和修改稿<br>2023.03.28,Review Finalized<br>2023.04.07,accepted <br>2023.04.12,Author's Proof,要求两天内提交<br>2023.04.25,支付版面费,2020 USD,限期一个月<br>2023.04.28,在线发表。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Fri May 05 09:41:42 CST 2023, time=2023-05-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2194551, encodeId=373b219455142, content=偏重的研究方向:肿瘤;免疫治疗;生信<br>经验分享:这个需要多久到分配编辑呀,在initial validation 4.5天了…… 生信又做了6个验证试验,不知道稳不稳…, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=46cb9200514, createdName=ms4000000517261689, createdTime=Thu Mar 21 20:31:46 CST 2024, time=2024-03-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2185007, encodeId=b593218500e2a, content=审稿速度:1.0<br>偏重的研究方向:诊断;肿瘤;临床<br>经验分享:临床诊断模型 1/12投稿 1/18分配编辑 1/31 开始review 后续更新, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/BLo7MYzN0oco8oufpibiaZiaic2nwPWGDsj6pRZzAVnvXic6m050K7ibRdibQgXNm6pFgeChrhQN10zP5nXicHp32QTvGA/132, createdBy=1ef65404738, createdName=mastermaus, createdTime=Wed Jan 31 10:14:15 CST 2024, time=2024-01-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2192636, encodeId=499d219263609, content=审稿速度:24.0 | 投稿命中率:5.0<br>偏重的研究方向:肿瘤<br>经验分享:其实是很难的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eca29108716, createdName=第一篇一定要中啊, createdTime=Mon Mar 11 19:29:12 CST 2024, time=2024-03-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向:肿瘤<br>经验分享:来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右,这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=290, replyNumber=71, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2151127, encodeId=429b215112e2a, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:症状管理;急性白血病<br>经验分享:来还愿了。分享一下历程。Received date: 09 Jun 2023<br>Editorial assignment start date: 13 Jun 2023<br>Independent review start date: 19 Jun 2023<br>Interactive review activated date: 05 Jul 2023<br>Review finalized date: 24 Jul 2023<br>Final validation date: 02 Aug 2023<br>Manucript accepted: 02 Aug 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477a5626989, createdName=ms3000001338105201, createdTime=Thu Aug 03 16:40:57 CST 2023, time=2023-08-03, status=1, ipAttribution=广东省)]
    2023-08-03 ms3000001338105201 来自广东省

    审稿速度:2.0 | 投稿命中率:50.0
    偏重的研究方向:症状管理;急性白血病
    经验分享:来还愿了。分享一下历程。Received date: 09 Jun 2023
    Editorial assignment start date: 13 Jun 2023
    Independent review start date: 19 Jun 2023
    Interactive review activated date: 05 Jul 2023
    Review finalized date: 24 Jul 2023
    Final validation date: 02 Aug 2023
    Manucript accepted: 02 Aug 2023

    3

    展开3条回复
共500条页码: 1/50页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分